These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 25172241)

  • 21. Efficacy and patient satisfaction in the use of subcutaneous immunoglobulin immunotherapy for the treatment of auto-immune neuromuscular diseases.
    Sala TP; Crave JC; Duracinsky M; Lepira Bompeka F; Tadmouri A; Chassany O; Cherin P
    Autoimmun Rev; 2018 Sep; 17(9):873-881. PubMed ID: 30005853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of IVIg in autoimmune neuropathies: the latest evidence.
    Hughes R
    J Neurol; 2008 Jul; 255 Suppl 3():7-11. PubMed ID: 18685920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and tolerability of different brands of intravenous immunoglobulin in the maintenance treatment of chronic immune-mediated neuropathies.
    Gallia F; Balducci C; Nobile-Orazio E
    J Peripher Nerv Syst; 2016 Jun; 21(2):82-4. PubMed ID: 26817673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expanding the Role of the Pharmacist: Immunoglobulin Therapy and Disease Management in Neuromuscular Disorders.
    Tichy EM; Prosser B; Doyle D
    J Pharm Pract; 2022 Feb; 35(1):106-119. PubMed ID: 32677504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years.
    Gentile L; Mazzeo A; Russo M; Arimatea I; Vita G; Toscano A
    Sci Rep; 2020 May; 10(1):7910. PubMed ID: 32404895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subcutaneous immunoglobulin for patients with idiopathic inflammatory myopathies: a real-world single centre experience.
    Ma Z; Johnson D; Gniadecki R; Ritchie B; Keeling S; Cohen Tervaert JW; Osman M
    Rheumatology (Oxford); 2023 Oct; ():. PubMed ID: 37796840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic evaluation of subcutaneous versus intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy: a real-life study.
    Piscitelli E; Massa M; De Martino BM; Serio CS; Guglielmi G; Colacicco G; Tuccillo F; Habetswallner F
    Eur J Hosp Pharm; 2021 Nov; 28(Suppl 2):e115-e119. PubMed ID: 33122403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subcutaneous immunoglobulin dose titration to clinical response in inflammatory neuropathy.
    Kapoor M; Keh R; Compton L; Morrow S; Gosal D; Manji H; Reilly MM; Lunn MP; Lavin TM; Carr AS
    J Neurol; 2021 Apr; 268(4):1485-1490. PubMed ID: 33608795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous immunoglobulins in the treatment of immune neuropathies.
    Kieseier BC; Meyer Zu Hörste G; Lehmann HC; Gold R; Hartung HP
    Curr Opin Neurol; 2008 Oct; 21(5):555-62. PubMed ID: 18769249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new treatment regimen with high-dose and fractioned immunoglobulin in a special subgroup of severe and dependent CIDP patients.
    Debs R; Reach P; Cret C; Demeret S; Saheb S; Maisonobe T; Viala K
    Int J Neurosci; 2017 Oct; 127(10):864-872. PubMed ID: 27918219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical applications of intravenous immunoglobulins in neurology.
    Hughes RA; Dalakas MC; Cornblath DR; Latov N; Weksler ME; Relkin N
    Clin Exp Immunol; 2009 Dec; 158 Suppl 1(Suppl 1):34-42. PubMed ID: 19883422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies.
    Barbasso Helmers S; Dastmalchi M; Alexanderson H; Nennesmo I; Esbjörnsson M; Lindvall B; Lundberg IE
    Ann Rheum Dis; 2007 Oct; 66(10):1276-83. PubMed ID: 17277004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparisons in fluctuation of muscle strength and function in patients with immune-mediated neuropathy treated with intravenous versus subcutaneous immunoglobulin.
    Christiansen I; Markvardsen LH; Jakobsen J
    Muscle Nerve; 2018 Apr; 57(4):610-614. PubMed ID: 28881389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 7(th) International Immunoglobulin Conference: Poster presentations.
    Warnatz K; Ballow M; Stangel M; Bril V
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):139-40. PubMed ID: 25546796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subcutaneous IgG in the Myositis Spectrum Disorders.
    Danieli MG; Gelardi C; Pedini V; Logullo F; Gabrielli A
    Curr Rheumatol Rev; 2018; 14(3):194-199. PubMed ID: 28292255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
    Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
    Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subcutaneous Immunoglobulin Therapy for Chronic Inflammatory Demyelinating Polyneuropathy: A Nursing Perspective.
    Watkins JM; Dimachkie MM; Riley P; Murphy E
    J Neurosci Nurs; 2019 Aug; 51(4):198-203. PubMed ID: 31107344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency.
    Igarashi A; Kanegane H; Kobayashi M; Miyawaki T; Tsutani K
    Clin Ther; 2014 Nov; 36(11):1616-24. PubMed ID: 25236916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis.
    Perraudin C; Bourdin A; Vicino A; Kuntzer T; Bugnon O; Berger J
    PLoS One; 2020; 15(11):e0242630. PubMed ID: 33237959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Role of Immunoglobulin in the Treatment of Immune-Mediated Peripheral Neuropathies.
    Tobon A
    J Infus Nurs; 2017; 40(6):375-379. PubMed ID: 29112586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.